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Chapter 1 
General introduction 
 
  Glutamine is one of the most abundant amino acids in food and the human body. 
However, glutamine is converted to L-2-pyrrolidone-5-carboxylic acid (pyroglutamic 
acid; pyroGlu) with condensation between the amino groups at α position and side chain 
in water. This reaction, which is irreversible, proceeds even in low temperature and is 
accelerated by heating (Sato et al., 1998; Suzuki et al., 1999). Peptides with a 
glutaminyl residue at the amino-terminus can be converted to pyroglutamyl peptide 
(Sato et al., 1998) as shown in Figure 1. It has been demonstrated that pyroglutamyl 
peptide is widely distributed in enzymatic hydrolysates of food proteins; they account 
for nearly 10% (w/w) in some cases (Sato et al., 1998; Suzuki et al., 1999). Short chain 
pyroglutamyl peptides resist amino peptidase digestion (Sato et al., 1998) and can be 
absorbed as peptides into the portal blood of rats after ingestion (Higaki-Sato et al., 
2006). In addition, it has been demonstrated that some pyroglutamyl peptides in wheat 
gluten hydrolysates exert biological activities. PyroGlu-Pro, pyroGlu-Pro-Ser, 
pyroGlu-Pro-Glu, and pyroGlu-Pro-Gln show umami taste (Schlichtherle-Cerny et al., 
2002). More recently, it has been demonstrated that pyroGlu-Leu attenuates 
D-galactosamine induced acute hepatitis in rat (Sato et al., 2013) and dextran sulfate 
sodium induced colitis in mice (Wada et al., 2013). 
  Japanese fermented foods such as soy sauce, shoyu, and Japanese rice wine, sake, are 
prepared using Aspergillus oryzae, which produces extracellular acid proteinases and 
acid carboxypeptidases (Kitano et al., 2002; Rao et al., 1998). Large amounts of amino 
acid and short-chain peptides are produced by these enzymes. In addition, these foods 
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contain relatively high contents of free pyroGlu (Ito et al., 2013; Tadenuma, M., 1966), 
which suggests the presence of short-chain pyroglutamyl peptides in these fermented 
foods. Recently, pyroGlu-Gln and pyroGlu-Gly were identified in shoyu and 
demonstrated to enhance the umami taste (Kaneko et al., 2011). However, there is still 
limited information on the structure of the pyroglutamyl peptides present in these 
fermented foods.  
  Japanese rice wine, sake, is a traditional fermented alcoholic beverage made from 
steamed rice, water, and lactic acid using fermentation with two microorganisms. The 
rice for sake brewing is polished to 45–70% of the starting material by dry milling 
before steaming. A part of the steamed rice is inoculated with A. oryzae, incubated at 
approximately 30°C for a few days, and used as mold starter (koji). Koji, another part of 
the steamed rice, and water are mixed and acidified by addition of lactic acid to 
suppress the growth of various non-acid-resistant microorganisms, and then inoculated 
with sake brewer’s yeast (Saccharomyces cerevisiae). The mixture is incubated at 15–
20°C for approximately 1 week to increase the amount of yeast, which is used as sake 
yeast starter (shubo). The other part of steamed rice, water, and koji are added to shubo 
(three times) and fermented for approximately 20 days after the final, third addition 
step; this mixture is referred to as sake mash (moromi). Moromi is pressed between 
cloths to obtain the liquid phase. This liquid is pasteurized to inactivate the 
microorganisms, and then mixed with alcohol for brewing and water if necessary. 
Completed sake contains various oligosaccharides, amino acids and peptides derived 
rice starch and protein, respectively, because A. oryzae secretes extracellular amylases 
and proteases. 
  Some unique compounds with potential health-promoting activities have been 
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identified in sake. It has been demonstrated that ethyl α-D-glucoside is produced by A. 
oryzae transglutaminase during sake brewing (Imanari et al., 1971; Oka et al., 1976), 
which has potential to moderate UVB-induced epidermal barrier disruption (Hirotsune 
et al., 2005) and D-galactosamine-induced hepatitis (Izu et al., 2007) by oral 
administration in animal models. Short chain peptides in sake have been demonstrated 
to have inhibitory activities against angiotensin I converting enzymes (Saito et al., 1992 
and 1994 a) and prolyl endpeptidase (Saito et al., 1997), and exert anti-hypertensive 
activity in a spontaneous hypertensive rat by oral administration (Saito et al., 1994 b). 
  To my best knowledge, there is, however, no information on short-chain 
pyroglutamyl peptides in sake. The objective of the present study was to identify the 
pyroglutamyl peptides in sake, which is one of the salt-free fermented alcohol beverages 
using A. oryzae with high amylases and proteases activity, to obtain basic knowledge of 
the pyroglutamyl peptides in sake and explore their potential health-promoting effects. 
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Figures 
 
 
Figure 1. Production of pyroglutamyl peptide from peptide with a glutaminyl residue at 
the amino-terminal position. 
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Chapter 2 
Identification of pyroglutamyl peptides from sake: presence of 
hepatoprotective pyroGlu-Leu 
 
Introduction 
 
  As mentioned in chapter 1, pyroglutamyl peptide is widely distributed in enzymatic 
hydrolysate of food protein (Sato et al., 1998; Suzuki et al., 1999). Recent studies has 
reported the various beneficial effects of short-chain pyroglutamyl peptides in food 
protein hydrolysate, such as enhancing umami taste (Schlichtherle-Cerny et al., 2002), 
attenuating acute hepatitis (Sato et al., 2013) and colitis (Wada et al., 2013), which 
indicate that food-derived pyroglutamyl peptide may have the beneficial effects for 
human health. 
  Japanese rice wine, sake is a traditional fermented alcoholic beverage made from 
steamed rice, water, and lactic acid using multiple parallel fermentation (see chapter 1 
for detail). In Japan, sake is not only consumed as alcohol beverage, but also used as 
one of major ingredients for Japanese cuisine, which is frequently used to add special 
flavor and taste to Japanese style dishes. As mentioned in chapter 1, sake may contain 
unique bioactive compounds including short-chain pyroglutamyl peptides. Therefore, 
daily intake of these compounds in sake might affect human health. However, there is 
very limited information on the pyroglutamyl peptides present in sake. 
  The objective of study in chapter 2 was to obtain basic knowledge of the 
pyroglutamyl peptides in sake. 
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Materials and methods 
 
1. Samples. 
  Five bottles of commercially available sake were obtained from different suppliers 
(A–E). In all cases, rice that had been polished to 60% was used. 
  Steamed rice was prepared from three different cultivars for sake brewing 
(Yamadanishiki, Nihonbare, and Gohyakumangoku) that had been polished to 45%, 60%, 
and 60%, respectively. The polished rice was soaked in water for 1 h and then steamed 
at 120°C for 45 min on an industrial scale at Shotoku Brewery (Kyoto, Japan). Koji, 
shubo, and moromi were also prepared from 60% polished rice on an industrial scale at 
the Shotoku Brewery. The steamed rice was cooled and inoculated with brewers’ grade 
Aspergillus oryzae, (Hishiroku, Kyoto, Japan), incubated at 30°C for 2 days, and then 
used as koji. The koji from 40 kg of polished rice was mixed with water (160 L) 
containing 1 L of food-grade lactic acid (Musashino Chemical Laboratory, Tokyo, 
Japan). The mixture was stirred thoroughly and inoculated with 1.2 L of slant culture 
medium of sake brewers’ yeast (Saccharomyces cerevisiae; Kyokai No. 9, Brewing 
Society of Japan, Tokyo, Japan). Then, steamed rice from 90 kg of polished rice was 
added. The mixture was incubated at approximately 22°C for 4 days and at 14°C for 
additional 2 days with stirring. The final product was used as shubo. Another part of the 
steamed rice, water and koji were added to shubo (three times). This mixture was 
incubated at approximately 10°C for 20 days and used as moromi. These products were 
brought to our laboratory in an ice box and stored at –20°C until use. 
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2. Reagents. 
  Pyrococcus furiousus pyroglutamate aminopeptidase was purchased from Takara Bio 
(Otsu, Japan). Protease and Taka-diastase from A. oryzae were purchased from 
Sigma-Aldorich (St. Louis, MO). L-Leucine (1-
13
C, 99%) was purchased from 
Cambridge Isotope Laboratories (Andover, MA). Phenyl isothiocyanate (PITC), 
acetonitrile (HPLC grade), and trifluoroacetic acid (TFA) were purchased from Wako 
Chemicals (Osaka, Japan). Triethylamine (TEA) was purchased from Thermo Fisher 
Scientific (Waltham, MA). Other reagents were of analytical grade or better. 
 
3. Fractionation of peptides in sake. 
  To separate pyroglutamyl peptides from peptides with an amino group, solid-phase 
extraction using a strong cation exchange resin was performed as described previously 
(Higaki-Sato et al., 2006). The strong cation exchange resin (AG50W-x8, hydrogen 
form, 100–200 mesh, Bio-Rad Laboratories, Hercules, CA) was washed with 50% 
methanol and packed into a spin column (15  7 mm i.d., 5.0 μm pore size, 
Ultrafree-MC, Millipore, Billerica, MA, Division of Merck, Darmstadt, Germany). 
Then, 200 μL of 10 mM HCl was added onto the column and eluted by centrifugation at 
7,000 rpm for 1 min for equilibration (three times). The resin can capture amino acids 
and peptides with an amino group in the presence of 75% ethanol (Aito-Inoue et al., 
2006). Next, 200 μL of sake (supplier A) was loaded onto the column and eluted by 
centrifugation. This procedure was repeated 10 times. After elution of the sample, the 
resin was washed with 100 μL of 50% methanol (twice). Unabsorbed effluents, which 
contained pyroGlu and pyroglutamyl peptides, were combined, dried under vacuum, 
and then dissolved in 200 μL of 0.1% (v/v) TFA containing 30% (v/v) acetonitrile. 
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  The sample was clarified by passing through a spin column packed with Sephadex 
G-25 fine grade (GE Healthcare, Buckinghamshire, U.K.), which was pre-equilibrated 
with 0.1% TFA containing 30% acetonitrile, as described earlier. After passing the 
sample, the spin column was washed with 50 μL of 0.1% TFA containing 30% 
acetonitrile. The effluents were combined. The clarified sample (200 μL) was loaded 
onto a size exclusion chromatography (SEC) column, Superdex Peptide 10/30 GL (GE 
Healthcare), which was equilibrated with 0.1% TFA containing 30% acetonitrile at flow 
rate of 0.5 mL/min. Fractions were collected every 1 min from 10 to 50 min 
corresponding to fractions 11–50. 
 
4. Identification of pyroglutamyl peptides. 
  The sequence of the pyroglutamyl peptides was determined by the method as 
described previously (Higaki-Sato et al., 2003). Two sets of aliquots (100 μL) of the 
SEC fractions were transferred to 1.5-mL centrifugal tubes and dried under vacuum. 
One set was used as blank, and the other set was used for pyroglutamate aminopeptidase 
digestion. To the blank tubes was added 100 μL of 50 mM sodium phosphate buffer, pH 
7.0, containing 10 mM dithiothreitol and 1 mM ethylenediaminetetraacetic acid. To the 
tubes used for the digestion were added 80 μL of the same buffer and 20 μL of 
pyroglutamate aminopeptidase solution (0.4 mU/20 μL of the same buffer). The 
enzymatic reaction was carried out at 60°C for 1 h. The reaction was terminated by 
drying under vacuum. The amino groups liberated by pyroglutamate aminopeptidase 
digestion were reacted with PITC. The resultant phenyl thiocarbamyl (PTC) derivatives 
were resolved by reversed phase-high performance liquid chromatography (RP-HPLC) 
as described previously (Higaki-Sato et al., 2003). Peaks that appeared only in the 
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pyroglutamate aminopeptidase digest were collected. The fractions were dried under 
vacuum. To residual PTC derivatives, was added 20 μL of a “redrying solution” 
consisting of methanol, water, and TEA (7:1:2), and the mixture was redried under 
vacuum to remove ammonia. Then, the residues were dissolved in 30% methanol and 
applied to an automatic peptide sequencer that operated on the basis of the Edman 
degradation (PPSQ-21, Shimadzu, Kyoto, Japan). Programs of the peptide sequencer 
were changed to start from the cleavage reaction with TFA (Sato et al., 1999).  
  SEC fractions that were not subjected to pyroglutamate aminopeptidase digestion or 
derivatization with PITC were also subjected to electrospray ionization-ion trap mass 
spectrometry (ESI-MS) and -tandem mass spectrometry (ESI-MS/MS) analyses. 
Aliquots of SEC fractions (100 μL) were mixed with 4 volumes of 0.1% formic acid 
containing 50% acetonitrile and directly injected to a LCQ (Thermo Fisher Scientific) or 
API 3200 (AB Sciex, Foster City, CA) using a syringe pump. The detection of parent 
and product ions were performed in positive mode and optimized using the auto tune 
program (Xcaliber, Thermo Fisher Scientific or Analyst, AB Sciex). 
 
5. Production of pyroGlu-Leu by yeast. 
  To examine the production of pyroGlu-Leu by sake brewers’ yeast (S. cerevisiae), 
three yeast preparations were inoculated into koji hot-water extracts. Koji hot-water 
extracts were prepared on laboratory scale as described previously (Asano et al., 1999) 
with a slight modification. Koji, steamed rice, and distilled water were mixed in the 
ratio 1:1:2 (volume) and then incubated overnight at 55°C. The extracts were clarified 
by passing through a filter paper (No. 5C, Advantec, Tokyo, Japan), and adjusted to 5° 
Baume with distilled water, and then sterilized in an autoclave at 120°C for 20 min. 
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Three strains of yeast (Koshi No. 2, 2NF, and 221) from the Kyoto Municipal Institute 
of Industrial Technology and Culture (Kyoto, Japan) were used. A loopful of these yeast 
slant cultures was transferred to 40 mL of sterilized koji hot-water extract and incubated 
at 30°C for 3 days without shaking. The mediums were clarified by passing through the 
filter paper as described above and used in the subsequent liquid chromatography–
tandem mass spectrometry (LC–MS/MS) analysis. 
 
6. Production of pyroGlu-Leu from 
13
C-Leu added in shubo. 
  To investigate the production of pyroGlu-Leu from free Leu in shubo, 1-
13
C-labeled 
Leu was added to the shubo. The production of pyroGlu-
13
C-Leu was monitored by LC–
MS/MS as described below. Shubo, which was prepared in an industrial scale at the 
Shoutoku brewery, was homogenized using a blender (Ace Homogenizer, Nihonseiki, 
Tokyo, Japan). The homogenate (1.5 g) was placed into 2.0-mL centrifugal tubes. 
Various concentrations of aqueous 
13
C-Leu solutions (100 μL) were added to the 
homogenates to give final concentrations of 0.5, 1.0, 2.5, and 5.0 μmol/g. The 
homogenate to which no 
13
C-Leu was added was used as blank. These reaction mixtures 
were incubated at 22°C for 4 days and at 14°C for an additional 2 days with shaking. 
Aliquots of these samples were collected every day and mixed with the same volume of 
distilled water. The samples were centrifuged at 13,000 rpm for 5 min. The supernatants 
were mixed with 3 volumes of ethanol. The resultant precipitates were removed by 
centrifugation. The ethanol-soluble fractions (200 μL) were subjected to solid-phase 
extraction as described above. Unabsorbed effluents were combined and then dried 
under vacuum. The dried fractions were dissolved with distilled water (200 μL) and 
clarified by passing through a filter (Cosmonice filter W, 4 mm i.d., 0.45 μm pore size, 
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Nacalai Tesque, Kyoto, Japan). The clarified samples (180 μL) were injected to a 
RP-HPLC column, Inertsil ODS-3 (250  4.6 mm i.d., 5 μm, GL Science, Tokyo, Japan), 
which was equilibrated with 0.1% formic acid at a flow rate of 1.0 mL/min. Elution was 
performed using a binary linear gradient that consisted of 0.1% formic acid (solvent A) 
and 0.1% formic acid containing 80% acetonitrile (solvent B). The gradient profile was 
as follows: 0–15 min, B 0–50%; 15–15.1 min, B 50–100%; 15.1–20 min, B 100%; 20–
20.1 min, B 100–0%; 20.1–30 min, B 0%. The column was maintained at 45°C. The 
pyroGlu-Leu fraction, which was eluted between 15.5 and 16.5 min, was collected and 
used in the subsequent LC–MS/MS analysis. 
 
7. Enzymatic digestion of steamed rice. 
  To investigate the production of pyroGlu-Leu from rice proteins by protease digestion, 
steamed rice prepared from three cultivars of rice grain was digested with A. oryzae 
enzymes. Steamed rice was homogenized with 2.2 volumes of distilled water using a 
blendar. Aliquot of the homogenate (10 g) was mixed with 10 mL of distilled water and 
digested by 18.6 mg of Taka-diastase and 12.5 mg of a protease from A. oryzae at 50°C 
for 5 h with shaking. Then, the reaction mixture was centrifuged at 3,000 rpm for 10 
min. The supernatant was mixed with 3 volumes of ethanol. The pyroGlu-Leu fraction 
was prepared from the ethanol-soluble fraction by RP-HPLC as described above and 
used in the subsequent LC–MS/MS analysis. 
 
8. Amino acid analysis. 
  Vapor-phase 6 M HCl hydrolysis was performed according to the method of 
Bidlingmeyer et al. (1984). Briefly, amino acids were derivatized with PITC, and the 
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resulting PTC-amino acids were resolved by applying the same condition used for the 
PTC-peptides as described above. 
 
9. Determination of pyroGlu-Leu using LC–MS/MS. 
  PyroGlu-Leu in koji was extracted with water. Koji was mixed with water at a weight 
ratio of 15:85 and homogenized using a glass homogenizer. Shubo and moromi were 
homogenized without adding water. These suspensions were centrifuged at 2,000 rpm 
for 20 min. The supernatants were diluted (1:10) with distilled water. In case of the 
bottled sake, a sample was directly diluted with distilled water. The yeast-inoculated 
koji hot-water extracts were diluted with distilled water (1:10). These samples (200 μL) 
were subjected to solid-phase extraction using the strong cation exchange resin as 
described above. The unabsorbed fractions were collected and dried under vacuum. The 
dried samples were dissolved in 200 μL of ultrapure water; and then, aliquots of the 
samples were diluted with ultrapure water (1:10) and filtered using a Cosmonice filter 
W. The pyroGlu-Leu fractions from 
13
C-Leu-added shubo (300 μL) and the enzyme 
digests of steamed rice (1 mL) were dried under vacuum and dissolved in 100 μL and 1 
mL of ultrapure water, respectively. The amounts of pyroGlu-Leu in these samples were 
determined using an LC–MS/MS that consisted of the Prominence 20A HPLC system 
(Shimadzu), the API 3200, and an Inertsil ODS-3 column (250  2.1 mm i.d., 5 μm). 
The column was equilibrated with 0.1% formic acid containing 5% acetonitrile at a flow 
rate of 0.2 mL/min. Elution was performed using a binary linear gradient consisting of 
0.1% formic acid containing 5% acetonitrile (solvent A) and 0.1% formic acid 
containing 80% acetonitrile (solvent B). The gradient profile was as follows: 0–15 min, 
B 0–80%; 15–15.1 min, B 80–100%; 15.1–20 min, B 100%; 20–20.1 min, B 100–0%, 
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20.1–30 min, B 0%. The column was maintained at 40°C. Detection was performed by 
multi reaction monitoring in positive mode. Multi reaction monitoring conditions were 
optimized using Analyst Version.1.4.2 (AB Sciex). 
 
10. Statistical analysis. 
  The pyroGlu-Leu contents at the different brewing steps of sake were expressed as 
mean of triplicate ± standard deviations. Differences between these mean were 
evaluated by Tukey’s test using Ekuseru-Toukei 2012 Version 1.11 (Social Survey 
Research Information, Tokyo, Japan). 
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Results 
 
1. Identification of short-chain pyroglutamyl peptides in sake. 
  Pyroglutamyl peptides and pyroGlu in the unabsorbed fraction obtained by 
solid-phase extraction were first fractionated by SEC based on the molecular mass. The 
elution of these compounds was monitored by amino acid analysis following HCl 
hydrolysis. As shown in Figure 1, nearly 80% of these compounds were eluted after 30 
min. On the basis of the elution volume, these fractions might contain peptides with a 
molecular mass of less than approximately 1,000 Da. Fractions (Fr.) 30–40 were 
considered to be short-chain pyroglutamyl peptide fractions and used for subsequent 
analyses. 
  The compounds in SEC Fr. 30–40 of samples that had or had not been subjected to 
pyroglutamate aminopeptidase digestion were reacted with PITC. The resultant 
PTC-amino acids and -peptides were resolved by RP-HPLC and detected at 254 nm. As 
shown in Figure 2, some peaks appeared only after pyroglutamate aminopeptidase 
digestion, indicating that they could be potentially derived from pyroglutamyl peptides. 
These peaks were collected and subjected to Edman degradation analysis. Peaks marked 
with letters (a–s) yielded phenyl thiohydantoin (PTH)-amino acids, while peaks marked 
with an asterisk did not. On the basis of the Edman degradation analysis of the PTC 
derivatives (peaks a–s in Figure 2), the estimated sequences of pyroglutamyl peptides in 
sake (supplier A) are listed in Table 1. PTC derivatives (peaks c, i, j, l, n. o, p, q, r, and s 
in Figure 3) showed the same retention time PTC-Val, -Leu, -Gln, -Met, -Tyr, -Phe, 
-Asn, -Ser, -Gly, and -Ala, respectively, which supports the validity of the estimated 
structures as summarized in Table 1. SEC Fr. 38–40 did not yield significant amounts of 
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PTC derivatives that could yield PTH-amino acids even after pyroglutamate 
aminopeptidase digestion; however, they yielded Glu after HCl hydrolysis (Figure 1). It 
has been demonstrated that free pyroGlu is eluted in these fractions under the same 
condition. These facts indicate that Fr. 38–40 predominantly consist of free pyroGlu. 
  To further confirm the sequences of the pyroglutamyl peptides listed in Table 1, SEC 
Fr. 32–37 that had not been subjected to pyroglutamate aminopeptidase digestion were 
subjected to ESI-MS and ESI-MS/MS analyses. The MS spectrum of SEC Fr. 34 is 
shown in Figure 3A. Ion peaks with m/z values of 229.1 (c), 243.0 (i), 299.9 (e), 357.1 
(b), and 390.9 (h) were observed, which correspond to protonated ions of pyroGlu-Val, 
pyroGlu-Leu, pyroGlu-Val-Ala, pyroGlu-Asn-Ile, and pyroGlu-Asn-Phe, respectively. 
The major ion with an m/z value of 243.0 corresponding to pyroGlu-Leu was subjected 
to MS/MS analysis. As shown in Figure 3B, product ions from pyroGlu-Leu were 
observed that correspond to the y1 ion, the loss of a water group, and the loss of a 
carboxyl group. These data also confirm the presence of pyroGlu-Leu in SEC Fr. 34. As 
summarized in Table 1, all protonated parent ions and their fragment ions were observed 
by MS and MS/MS analyses. Details for MS and MS/MS patterns are shown in the 
supplemented data attached in the end of this chapter. Together with the results obtained 
using Edman degradation analysis, the presence of pyroglutamyl peptides as listed in 
Table 1 in sake is strongly indicated. 
  As shown in Figure 2, pyroGlu-Leu and pyroGlu-Gln were the major constituents of 
the pyroglutamyl peptides in sake (supplier A). On the basis of the peak areas shown in 
Figure 2, the pyroGlu-Leu and pyroGlu-Gln contents were estimated to be 
approximately 36.2% and 21.3% of the total pyroglutamyl peptides, respectively. 
 
  19 
 
2. PyroGlu-Leu content in sake. 
  Figure 4I shows pyroGlu-Leu content in commercially available sake from different 
suppliers. In all cases, pyroGlu-Leu was detected at concentrations ranging from 40 to 
60 μM (10–15 mg/L). Figure 4II shows the pyroGlu-Leu content at different steps of 
sake brewing. Whereas the water extract of koji contained less than 0.1 μM (0.02 
mg/mL) pyroGlu-Leu, shubo at 2 days after mixing contained 23.2 μM (6 mg/L) 
pyroGlu-Leu. The pyroGlu-Leu content tentatively decreased in moromi on the first day 
(odori) because new ingredients were added to shubo but also increased significantly 
during the shubo and moromi processes. 
 
3. Production of pyroGlu-Leu. 
  First, the production of pyroGlu-Leu by yeast (Saccharomyces cerevisiae) was 
examined. Three types of sake brewers’ yeast preparation were inoculated into koji 
hot-water extracts. After incubation at 30°C for 3 days, no increase in the pyroGlu-Leu 
content was observed (Figure 5).  
  Second, the production of pyroGlu-Leu from free Leu in shubo was examined. The 
ratio of pyroGlu-
13
C-Leu to pyroGlu-
12
C-Leu in shubo, to which different amounts of 
13
C-Leu had been added, was determined by monitoring the immonium ions of 
12
C-Leu 
and 
13
C-Leu from pyroGlu-Leu (m/z 243.1 > 86.1, and 244.1 > 87.1), respectively. As 
shown in Figure 6A and B, the amount of both forms of pyroGlu-Leu consisting of 
12
C-leu and 
13
C-Leu increased during the incubation of shubo. However, the ratio of 
13
C-Leu to 
12
C-Leu in pyroGlu-Leu did not increase after addition of 
13
C-Leu (Figure 
6C), even at 5 μmol/g of shubo, which was five times more than the Leu content 
originally present in shubo. These results indicate that only a negligible amount of 
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pyroGlu-Leu was produced from free Leu in shubo. 
  Third, the production of pyroGlu-Leu by proteolysis of rice proteins by A. oryzae 
enzymes was examined. As shown in Figure 6D, pyroGlu-Leu was produced from 
steamed rice and reached a concentration of 7 μM (2 mg/L) in the reaction mixtures 
from three different rice cultivars by enzyme treatment, whereas steamed rice contained 
only a negligible amount of pyroGlu-Leu before digestion. 
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Discussion 
 
  As summarized in Table 1, 19 pyroglutamyl peptides were identified in sake, which 
for the first time provides basic knowledge about the structure of pyroglutamyl peptides 
in sake. Among them, pyroGlu-Gln and pyroGlu-Leu were major constituents (Figure 2). 
The presence of pyroGlu-Gln has also been demonstrated in Japanese-style soy sauce, 
shoyu, at 1.6 mM (Kaneko et al., 2011). It has been demonstrated that pyroGlu-Gln 
enhances umami taste at approximately 0.3 mM. The sake (supplier A) contained 
pyroGlu-Gln at approximately 35 μM. Sake is frequently used in Japanese cuisine to 
enhance flavor and taste. Depending on the recipe, relatively large volumes of sake 
(compared shoyu) are used. Thus, pyroglutamyl peptides in sake, including 
pyroGlu-Gln, can contribute to improving the flavor and taste of traditional Japanese 
dishes. 
  PyroGlu-Leu, the major constituent of pyroglutamyl peptides in sake, was first 
identified in a wheat gluten hydrolysate, which improved hepatitis (Sato et al., 2013) 
and colitis (Wada et al., 2013) at low doses (20 and 0.1 mg/kg body weight, 
respectively) in animal models. The present study demonstrated that pyroGlu-Leu is 
present in commercially available sake at concentrations ranging from more than 40 μM 
(10 mg/L) (Figure 4I). In addition, pyroGlu-Leu was not produced from free Leu in 
sake yeast starter, shubo, when too much amount of free Leu was added in the shubo 
(Figure 6A–C). However, this peptide increased with digestion of rice protein by A. 
oryzae (Figure 6D). PyroGlu-Leu has been demonstrated to resist protease digestion 
(Sato et al., 2013). Therefore, pyroGlu-Leu may not be degraded in the sake brewing 
process. In addition, A. oryzae secretes proteases into the extracellular medium (Rao et 
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al., 1998 and Kitano et al., 2002), whereas yeast and lactic acid bacteria do not (Rao et 
al., 1998 and Savijoki et al., 2006). With these facts, it can be concluded that A. oryzae 
proteases play a significant role in the production of pyroGlu-Leu in sake brewing. 
Therefore, non-alcoholic food ingredients rich in pyroGlu-Leu can be produced from 
rice and other protein sources by fermentation with A. oryzae or digestion by its 
proteases, which have the potential for improving hepatitis and colitis in human. 
  In addition to pyroGlu-Leu, nearly 20 pyroglutamyl peptides, whose biological 
activities remain to be determined, were identified in sake. In the following chapters, the 
results on the biological activities of the other pyroglutamyl peptides in sake and on the 
production of pyroGlu-Leu by A. oryzae fermentation are reported. 
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Figures and tables 
 
 
Figure 1. Elution profile of peptides in the unabsorbed fractions of solid-phase 
extraction of sake by size exclusion chromatography (SEC) using Superdex Peptide 
10/30 GL (GE Healthcare). Peptide contents are expressed as the sum of the constituting 
amino acids in the SEC fractions after HCl hydrolysis. Free pyroglutamic acid and 
pyroglutamyl residues in peptides are converted to glutamic acid by the HCl hydrolysis.  
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Figure 2. Isolation of phenyl thiocarbamyl-amino acids/-peptides in pyroglutamate aminopeptidase 
digests (+) and non-digests (−) of size exclusion chromatography fractions 30–40. Peaks marked with 
letters yielded phenyl thiohydantoin (PTH)-amino acids upon Edman degradation. Peaks marked with 
an asterisk did not yield PTH-amino acids. 
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Figure 3. Electrospray ionization-mass spectrometry (ESI-MS) spectrum of the intact compounds in size 
exclusion chromatography fractions 34 (A) and ESI-tandem mass spectrometry (MS/MS) spectrum of 
the peak with an m/z value of 243.0 (B). Peaks marked with letters in panel A have m/z values of 
precursor ions corresponding to the estimated pyroglutamyl peptides indicated with the same letters in 
Table 1.  
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Figure 4. PyroGlu-Leu content in commercially available sake from five different suppliers (I) and 
change in the content during the brewing process (II). “Shubo 2 days” and “7 days” indicate 2 and 7 
days after mixing the materials of shubo, respectively. “Moromi odori” refers to the first addition of 
steamed rice, water, and koji to completed shubo (7 days), and “moromi age” means completed 
moromi at approximately 20 days after the final, third addition step. Data are shown as mean ± 
standard deviations (n = 3). Different letters indicate a significant difference by Tukey’s test (p < 0.05).
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Figure 5. PyroGlu-Leu content in koji hot-water extracts three days after inoculation of three strains of 
brewers’ yeast (Koshi No. 2, 221, and 2NF). The extracts were kept at 30°C for three days. Medium: the 
koji hot-water extract without inoculation of yeast. 
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Figure 6. Production of pyroGlu-Leu by incubation of shubo (A–C) and digestion of steamed rice by 
Aspergillus oryzae enzymes (D). Different levels of 
13
C-Leu were added to shubo, and the production of 
pyroGlu-
12
C-Leu (A), pyroGlu-
13
C-Leu (B), and the ratio of pyroGlu-
13
C-Leu/-
12
C-Leu (C) are shown. 
Shymbols: (●) 0; (○) 0.5; (▲) 1.0; (△) 2.5; (□) 5.0 μmol/g of 1-13C-Leu in shubo. Contents of 
pyroGlu-
12
C-Leu and pyroGlu-
13
C-Leu are expressed as peak areas of the immonium ion of 
12
C-Leu, 
m/z 243.1 > 86.1, and 
13
C-Leu, m/z 244.1 > 87.1, as arbitrary unit. PyroGlu-Leu content in samples of 
steamed rice from three different cultivars that had or had not been subjected to digestion by A. oryzae 
enzymes is shown in panel D. 
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Table 1. Sequences, precursor, and product ions of pyroglutamyl peptides in size exclusion chromatography (SEC) 
fractions of sake 
SEC Fr. Peak 
Peptide 
sequence* 
Precursor ion 
(m/z) 
Product ions (m/z) 
32 a 
pyroGlu-Asn-Ile- 
Asp-Asn-Pro 
683.4 
69.6 (immonium ion of Pro), 86.0 (immonium ion of Ile), 
116.0 (y1), 311.2 (a3), 339.1 (b3), 454.2 (b4), 568.2 (b5), 
666.2 ([M-NH3]
+
) 
33, 34 b 
pyropGlu-Asn-Il
e 
357.1 
225.9 (b2), 243.7 (c2), 158.1 (x1), 131.9 (y1), 272.8 (x2), 
229.4 (z2), 338.9 ([M − H2O]
+
) 
33, 34, 35 c pyroGlu-Val 229.1 118.5 (y1), 182.9 ([210.9 − CO]
+
), 210.9 ([M − H2O]
+
) 
33 d pyroGlu-Leu-Trp 428.9 
205.7 (y1), 188.1 (z1), 316. 7 (y2), 301.9 (z2), 411.1 ([M − 
H2O]
+
) 
33, 34 e pyroGlu-Val-Ala 299.9 183.0 (a2), 210.9 (b2), 115.7 (x1) 
33 f pyroGlu-Val-Pro 325.9 
112.9 (b1), 128.8 (c1), 182.2 (a2), 210.9 (b2), 116.0 (y1), 
214.9 (y2), 198.0 (z2) 
33 g pyroGlu-Val-Val 328.0 
183.1 (a2), 210.9 (b2), 144.3 (x1), 118.0 (y1), 243.1 (x2), 
283.3 ([M-COOH]
+
), 309.9 ([M − H2O]
+
) 
34, 35 
h 
pyroGlu-Asn-Ph
e 
390.9 
262. 7 (z2), 373.0 ([M − H2O]
+
) 
34, 35, 36 i pyroGlu-Leu 243.0 131.9 (y1), 197.0 ([224.9 − CO]
+
), 224.9 ([M − H2O]
+
) 
35, 36, 37 j pyroGlu-Gln 258.1 
129.1 (c1), 146.9 (y1), 212.9 ([M − COOH]
+
), 240.0 ([M − 
H2O]
+
) 
35, 36 k pyroGlu-Ser-Gln 345.1 
199.0 (b2), 215.9 (c2), 146.9 (y1), 129.9 (z1), 234.1 (y2), 
327.0 ([M − H2O]
+
) 
35 l pyroGlu-Met 260.9 149.9 (y1), 214.9 ([242.9 − CO]
+
), 242.9 ([M − H2O]
+
) 
36 m pyroGlu-Gly-Gln 314.9 
141.1 (a2), 169.0 (b2), 146.9 (y1), 129.9 (z1), 187.2 (z2),  
269.0 ([297.1 − CO]
+
), 297.1 ([M − H2O]
+
) 
36, 37 n pyroGlu-Tyr 293.0 182.0 (y1), 247.0 ([274.9 − CO]
+
), 274.9 ([M − H2O]
+
) 
36 o pyroGlu-Phe 276.9 166.0 (y1), 230.9 ([259.0 − CO]
+
), 259.0 ([M − H2O]
+
) 
37 p pyroGlu-Asn 244.2 132.9 (y1), 197.8 ([225.9 − CO]
+
), 225.9 ([M − H2O]
+
) 
37 q pyroGlu-Ser 216.9 106.0 (y1), 171.1 ([199.0 − CO]
+
), 199.0 ([M − H2O]
+
) 
37 r pyroGlu-Gly 187.1 84.0 (a1), 75.9 (y1), 169.1 ([M − H2O]
+
) 
37 s pyroGly-Ala 200.9 89.9 (y1), 155.1 ([182.9 − CO]
+
), 182.9 ([M − H2O]
+
) 
*Estimated sequences by mass spectrometry and tandem mass spectrometry analyses of SEC fractions, together with 
Edman degradation based on sequences of phenyl thiocarbamyl-amino acids of peptides in the pyroglutamate 
aminopeptidase digests (peaks a−s in Figure 3). 
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Supplemental figure 1. Electrospray ionization-mass spectrometry (ESI-MS) spectra of 
intact compounds in size exclusion chromatography (SEC) fractions 32, 33, 35, 36, and 
37. Peaks marked with letters show m/z of precursor ions corresponding to the estimated 
pyroglutamyl peptides indicated with the same letters in Table 1. 
 
  
Fr37 #27-213 RT: 0.51-4.01 AV: 187 NL: 7.20E5
T: + p ESI Full ms [50.00-1000.00]
150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300
m/z
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
500000
550000
600000
650000
700000
750000
In
te
n
s
it
y
288.13
254.87
212.00
187.13
271.93
249.87
257.93
289.27162.73 195.00
208.73
259.00
292.93
221.80 278.93265.93
294.00
213.00 247.13
280.00 295.93240.13149.07 203.60 232.07 298.93
216.93195.87
179.93157.07
238.87172.87
Fr. 37 MS
q
p
n
s
j
r
18 .1
200.9 216.9
244.2
257.9
29 .9
38 
 
 
Supplement figure 2. ESI-tandem mass spectrometry spectrum (ESI-MS/MS) of the 
peak a in the ESI-MS spectrum of SEC Fr. 32. Fragment ions for 
pyroGlu-Asn-Ile-Asp-Asn-Pro. 
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Supplement figure 3. ESI-MS/MS spectra of the peaks b, c, d, e, f, and g in the MS 
spectrum of SEC Fr. 33. Fragment ions of the sequences indicated on the spectra were 
observed. 
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Supplement figure 4. ESI-MS/MS spectra of the peaks b, c, e, and h in the MS spectrum 
of SEC Fr. 34. Fragment ions of the sequences indicated on the spectra were observed. 
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Supplement figure 5. ESI-MS/MS spectra of the peaks c, h, i, j, k, and l in the MS 
spectrum of SEC Fr. 35. Fragment ions of the sequences indicated on the spectra were 
observed. 
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Supplement figure 6. ESI-MS/MS spectra of the peaks i, j, k, m, n, and o in the MS 
spectrum of SEC Fr. 36. Fragment ions of the sequences indicated on the spectra were 
observed. 
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Fr37 #571-696 RT: 12.15-15.24 AV: 126 NL: 1.34E4
T: + p ESI Full ms2 244.23@cid30.00 [65.00-500.00]
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Supplement figure 7. ESI-MS/MS spectra of the peaks j, n, p, q, r, and s in the MS 
spectrum of SEC Fr. 37. Fragment ions of the sequences indicated on the spectra were 
observed.
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Chapter 3 
Identification of pyroglutamyl peptides with protective effect against 
dextran sulfate sodium (DSS)-induced colitis in mice from sake 
 
Introduction 
 
  Inflammatory bowel disease (IBD) is chronic disorder of gastrointestinal tract, 
including ulcerative colitis (UC) and Crohn’s disease (CD). UC is limited to the colon, 
whereas CD can occur in any parts of the gastrointestinal tract (Xavier et al., 2007). IBD 
patients suffer from diarrhea, bloody stool, and body weight loss, and etc. To treat IBD, 
anti-inflammatory medicine, enteral nutrient, and severe dietary limitation are generally 
used. However, these therapies exert limited efficacy and sometimes induce undesirable 
side effects. Therefore, many efforts have been focused to find natural compounds with 
protective effect against IBD from foods and food compounds (Camuesco et al., 2005; 
Osman et al., 2008; Larrosa et al., 2009; Shizuma et al., 2011; Young et al., 2012; Yoda 
et al., 2014). However, in most of these studies, high doses of the compounds are 
needed to exert beneficial effects in animal colitis models. 
  Recently, Wada et al. (2013) have reported that pyroGlu-Leu, which had been first 
identified from wheat gluten hydrolysate, attenuate dextran sulfate sodium 
(DSS)-induced colitis in mice by oral administration of low dose (0.1 mg/kg body 
weight). As shown in chapter 2, unexpectedly, pyroGlu-Leu is contained in sake as a 
major pyroglutamyl peptide. In addition to pyroGlu-Leu, sake contains nearly 20 
pyroglutamyl peptides with different structures. These pyroglutamyl peptides in sake 
may also have the protective effect against colitis as pyroGlu-Leu. Therefore, the 
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objective of study in chapter 3 was to identify new bioactive pyroglutamyl peptides 
from sake.  
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Materials and methods 
 
1. Samples. 
  A bottled Japanese rice wine, sake, which was made of rice polished to 60% and 
contains 15% (v/v) of alcohol, was commercially obtained from Shotoku Brewery 
(Kyoto, Japan), which had been prepared by the method as described in chapter 2. The 
sake was concentrated to 5-fold by a rotary evaporator at 60°C and used for following 
fractionation. 
 
2. Regents. 
  Dextran sulfate sodium (DSS, average molecular weight 8,000) was purchased from 
Seikagaku (Tokyo, Japan). Pyrococcus furiosus pyroglutamate aminopeptidase was 
purchased from Takara Bio (Otsu, Japan). Acetonitrile (HPLC grade), trifluoroacetic 
acid (TFA), and phenyl isothiocyanate (PITC) were purchased from Wako Chemicals 
(Osaka, Japan). Triethylamine (TEA) was purchased from Thermo Fisher Scientific 
(Waltham, MA). Free pyroglutamic acid and D-(+)-glucose (anhydrous) was purchased 
from Nacalai Tesque (Kyoto, Japan). 9-fluorenylmethoxycarbonyl 
(Fmoc)-Tyr(tBu)-wang resin, Fmoc-Ile-wang resin, H-Pro-2-chlorotritylchloride resin, 
Fmoc-Asn(Trt)-OH, Fmoc-Ile-OH, Fmoc-Asp(OtBu)-OH for peptide synthesis were 
purchased from HiPep Laboratories (Kyoto, Japan). Other reagents used were of 
analytical grade or better. 
 
3. DSS-induced colitis in mice. 
  Seven-week-old male C57BL/6 mice were purchased from Shimizu Laboratory 
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Supplies (Osaka, Japan). The mice were caged, 6–7 animals in each cage, in a room 
kept at 18–24°C and 40–70% relative humidity, with a 12 h light/dark cycle. The mice 
were allowed free access to drinking water and standard diet (CRF-1, Oriental Yeast, 
Kyoto, Japan) during a 1 week acclimatization period. All animals were treated and 
cared for in accordance with the National Institutes of Health’s (NIH) guidelines for the 
use of experimental animals. All experimental procedures were approved by the Animal 
Care Committee of Kyoto Prefectural University of Medicine (M23–37, M24–25, 
Kyoto, Japan). 
  Acute colitis was induced by addition of DSS into drinking water to give 2.5 or 3.0% 
(w/v) for 7 days according to the method employed in previous studies (Naito et al., 
2006; Takagi et al., 2011; Wada et al., 2013). The concentration of DSS (2.5% or 3.0%) 
was determined by preliminary experiments for the induction of the same grade (more 
than disease activity index score 2) of inflammation in each individual experiment as 
described in the previous paper (Wada et al., 2013), as the severity of DSS-induced 
colitis in mice depended on the animal lots. Samples were dissolved into distilled water 
and administered at 200 μL to the mice by oral gavage once per day during the entire 
colitis induction period. DSS-induced colitis mice with administration of 200 μL of 
distilled water were considered as vehicle group (DSS +). Mice without DSS solution 
were also administered 200 μL of distilled water, which was considered as normal group 
(DSS −). The body weight of each mouse was measured on days 0, 3, 5, and 7. The 
mice were sacrificed on day 7 and the entire colon was removed from the cecum to the 
anus. The colon length was measured as an indirect marker of inflammation, 
immediately after colon resection. 
  Colitis severity was evaluated on the basis of body weight, colon length, and the 
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macroscopic observations of stool and colon. The disease activity index (DAI) score 
was determined by the method employed in previous studies (Murano et al., 2000; Naito 
et al., 2006; Wada et al., 2013) using five grades of weight change (0, no loss or weight 
gain; 1, 1–5% loss; 2, 5–10% loss; 3, 10–20% loss; and 4, more than 20% loss), stool 
consistency (0, normal; 1, mild loose; 2, loose; 3, mild diarrhea; and 4, diarrhea), and 
stool bleeding (0, negative; 1, light bleeding; 2, mild bleeding; 3, severe bleeding; and 4, 
entire bleeding). The DAI score was obtained using an average of each criterion. 
 
4. Fractionation of sake compounds by preparative isoelectric focusing. 
  For the animal experiment, the compounds in the sake concentrate were first 
fractionated by preparative isoelectric focusing based on the amphoteric nature of the 
samples by the method of Hashimoto et al. (2005) with slight modification (Sato et al., 
2013). This method has been referred to as autofocusing. 0.1 M phosphoric acid and 0.1 
M sodium hydrate were loaded in the compartments at either ends of the tank, which 
were used as the anode and cathode compartments, respectively. The other 
compartments were used as sample compartments and were numbered from the anode 
side (No. 1) to the cathode side (No. 10). Sample compartments 8 and 9 were filled with 
500 mL of the 5-fold sake concentrate. The other sample compartments were filled with 
deionized water. Autofocusing was performed in constant voltage mode at 500 V for 24 
h. All autofocusing fractions were collected and adjusted to pH 7.0 by addition of 1 M 
HCl or NaOH solutions and used for following experiments. 
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5. Fractionation of sake compounds by preparative reversed-phase liquid 
chromatography (RP-LC). 
  The autofocusing fraction that exerted the protective effect against the DSS-induced 
colitis in mice was subjected to second fractionation using preparative reversed-phase 
liquid chromatography (RP-LC). The RP-LC system consisted of the column (161 mm 
 15 mm i.d., Millipore, Billerica, MA, Division of Merck, Darmstadt, Germany), 
which was packed with YFLC Gel ODS (50 μm particle size, 120 Å pore size, Yamazen, 
Osaka, Japan), a pump (FL600A, Yamazen), a gradient controller (Gradicon III 
AC-5900, Atto, Tokyo, Japan), and a gradient mixer (AC-5905, Atto). The column was 
equilibrated with 10 mM HCl at flow rate of 10 mL/min. Then, eighty milliliters of the 
autofocusing fraction that had been diluted to 3.0 mg peptides (total amino acids)/mL 
was loaded to the column using the pump. Elution was performed using a binary linear 
gradient that consisted of 10 mM HCl (solvent A) and 10 mM HCl containing 60% (v/v) 
(solvent B) acetonitrile. The gradient profile was B 0% for 1 min and followed by B 0–
100% over 20 min and then B 100% for 2 min. Fractions were collected every 0.5 min 
from sample injection corresponding Fr. 1–31. 
 
6. Identification of pyroglutamyl peptides. 
  Identification of pyroglutamyl peptides in the preparative RP-LC fraction was 
performed as described in chapter 2 with slight modification. Aliquot (4 mL) of the 
preparative RP-LC fraction that had exerted protective effect against the DSS-induced 
colitis in mice was dried under vacuum and dissolved in 400 μL of 0.1% (v/v) TFA 
containing 30% acetonitrile. The sample was clarified by passing through a spin column 
(15 mm  7 mm i.d., 5 μm pore size, Ultrafree-MC, Millipore) packed with Sephadex 
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G-25 fine grade (GE Healthcare, Buckinghamshire, UK), which was pre-equilibrated 
with the same solution. After passing the sample, the spin column was washed with 50 
μL of the same solution, and the effluents were combined (450 μL of total volume). 
Aliquot (200 μL) of the clarified sample was loaded onto a size exclusion 
chromatography (SEC) column, Superdex Peptide 10/30 GL (GE Healthcare), which 
was equilibrated with 0.1% TFA containing 30% acetonitrile at flow rate of 0.5 mL/min. 
Fractions were collected every 1 min from 20–45 min corresponding to fractions 21–45. 
This fractionation was performed twice. 
  Aliquots of the SEC fractions 31–45 were dried under vacuum and dissolved with 
200 μL of distilled water. The SEC fractions were subjected to solid phase extraction 
with a strong cation exchange resin (AG50W-x8, hydrogen form, 100–200 mesh, 
Bio-Rad Laboratories, Hercules, CA) to separate pyroglutamyl peptides from peptides 
with amino group as described in chapter 2. The samples (200 μL) were loaded onto 
spin columns packed with the resin, which had been equilibrated with 10 mM HCl 
containing 50% methanol, and eluted by centrifugation at 7,000 rpm for 1 min. The 
columns were washed with 100 μL of 50% methanol (twice). Unabsorbed effluents 
were combined and dried under vacuum, and then dissolved in 200 μL of distilled water. 
  These unabsorbed samples (80 μL) were injected to a reversed-phase high 
performance liquid chromatography (RP-HPLC) column, Inertsil ODS-3 (250  4.6 mm, 
5 μm pore size, GL Science, Tokyo, Japan), which had been equilibrated with 0.1% 
(v/v) formic acid at flow rate of 1.0 mL/min. Elution was performed using a binary 
linear gradient which consisted of 0.1% formic acid (solvent A) and 0.1% formic acid 
containing 80% acetonitrile (solvent B). The gradient profile was as follows: 0–30 min, 
B 0–30%; 30–35 min, B 30–100%; 35–40 min, B 100%; 40–40.1 min, B 100–0%; 
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40.1–50 min, B 0%. The column was maintained at 45°C. Elution was monitored at 214 
nm. Peaks were collected. The collected fractions were dried under vacuum and 
dissolved in 200 μL of 0.1% formic acid containing 30% acetonitrile. 
  Two sets of aliquots (100 μL) of the samples were transferred to 1.5-mL centrifugal 
tubes and dried under vacuum. One set was used as blank, and the other set was used for 
the pyroglutamate aminopeptidase digestion. To the blank tubes was added 100 μL of 50 
mM sodium phosphate buffer, pH 7.0, containing 10 mM dithiothreitol and 1 mM 
ethylendiaminetetraacetic acid. To the tubes used for the digestion were added 80 μL of 
the same buffer and 20 μL of pyroglutamate aminopeptidase solution (0.4 mU/20 μL of 
the same buffer). The enzyme reaction was carried out at 60°C for 1 h. The reaction was 
terminated by drying under vacuum. The amino groups liberated by the digestion were 
reacted with PITC. The resultant phenyl thiocarbamyl (PTC) derivatives were resolved 
by RP-HPLC as described in chapter 2. Peaks that appeared only in the enzyme digest 
were collected and dried under vacuum. A “redrying solution” (20 μL) consisting of 
methanol, water, and TEA (7:1:2) was added to the PTC derivatives, and redried under 
vacuum to remove ammonia. Then, the residues were dissolved in 30% methanol and 
applied to an automatic peptide sequencer that operated on the basis of the Edman 
degradation (PPSQ-21, Shimadzu, Kyoto, Japan). Programs of the peptide sequencer 
were changed to start from the cleavage reaction with TFA (Sato et al., 1999). 
 
7. Synthesis of pyroglutamyl peptides. 
  Pyroglutamyl-tyrosine (pyroGlu-Tyr), pyroglutamyl-asparaginyl-isoleucine 
(pyroGlu-Asn-Ile), and 
pyroglutamyl-asparaginyl-isoleucyl-asparagyl-asparaginyl-proline 
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(pyroGlu-Asn-Ile-Asp-Asn-Pro) were synthesized by an automatic solid-phase peptide 
synthesizer (PSSM-8, Shimadzu) according to the protocol provided by the supplier. 
The synthesized pyroglutamyl peptides were purified by RP-HPLC using an Inertsil 
ODS-3 (250  10 mm, 5 μm, GL Science) using acetonitrile/10 mM HCl solvent system. 
The content of these peptides were determined by amino acid analysis after HCl 
hydrolysis as described below. 
 
8. Amino acid analysis. 
  Samples were hydrolyzed with 6 M HCl vapor at 150°C using the method as 
described in chapter 2. The resultant amino acids were reacted with PITC, and the PTC 
amino acids were resolved using the same conditions for identification of pyroglutamyl 
peptides as described above. The contents of free amino acids were determined by 
amino acid analysis without HCl hydrolysis. 
 
9. Sugar analysis. 
  Samples were appropriately diluted with distilled water to give absorbance within 
standard curve. Concentrated sulfuric acid (150 μL) and 10% phenol (15 μL) were 
added to samples (30 μL) in 1.5-mL centrifugal tube and kept for 10 min. Then, the 
tubes were mixed and kept for additional 30 min. The reaction mixtures were 
transferred to a 96 well plate and monitored at 490 nm. The sugar contents of samples 
were presented as glucose equivalent. 
 
10. Determination of pyroglutamyl peptides. 
  The contents of pyroGlu-Leu, pyroGlu-Tyr, pyroGlu-Asn-Ile, and 
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pyroGlu-Asn-Ile-Asp-Asn-Pro in sake concentrate, autofocusing Fr. 8, and RP-LC Fr. 
III were determined using liquid chromatography-tandem mass spectrometry (LC–
MS/MS) as described in chapter 2 with slight modification. These samples were diluted 
at 10-folds with ultrapure water, and clarified by passing through a filter (Cosmonice 
filter W, 4 mm i.d., 0.45 μm pore size, Nacalai Tesque). The LC–MS/MS system was 
consisted of the Prominence 20A HPLC system (Shimadzu, Kyoto, Japan), the API 
3200 (AB Sciex, Foster City, CA), and an Inertsil ODS-3 column (250  2.1 mm i.d., 5 
μm, GL Science, Tokyo, Japan). The column was equilibrated with 0.1% formic acid 
containing 5% acetonitrile at a flow rate of 0.2 mL/min. Elution was performed using a 
binary liner gradient consisting of 0.1% formic acid containing 5% acetonitrile (solvent 
A) and 0.1% formic acid containing 80% acetonitrile (solvent B). The gradient profile 
was as follows: 0–15 min, B 0–50%; 15–15.1 min, B 50–100%; 15.1–20 min, B 100%; 
20–20.1 min, B 100–0%, 20.1–30 min, B 0%. The column was maintained at 40°C. 
Detection was performed by multi reaction monitoring in positive mode. Multi reaction 
monitoring conditions were optimized using Analyst Version.1.4.2 (AB Sciex). 
 
11. Microbiota analysis. 
  The inner contents of the colon were collected from mice in each group with single 
pyroglutamyl peptide ingestion. Population of phylum Bacteroidetes and Firmicutes 
were quantified on the basis of amplification of genome DNA coding 16S rRNA by 
polymerase chain reaction by using group-specific primers (Guo et al., 2008; Tannock 
et al., 2000). For detection of Bacteroidetes, Bact934F 
(GGARCATGTGGTTTAATTCGATGAT) and Bact1060R 
(AGCTGACGACAACCATGCAG) were used. For Firmicutes, Firm934F 
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(GGAGYATGTGGTTTAATTCGAAGCA) and Firm1060R 
(AGCTGACGACAACCATGCAC) were used. DNA was extracted using by QIAamp 
DNA StoolMini Kit (Qiagen, Venlo, Netherland) according to the instruction manual. 
Real-time PCR was done using a LightCycler 480 (Roche Applied Science, Manheim, 
German) according to SYBR Green I Master Protocol. PCR analysis was carried out in 
Primary Cell Division of Cosmo Bio (Sapporo, Japan). 
 
12. Statistical analysis. 
  The values of body weight change, colon length, and DAI score of DSS-induced 
colitis mice were presented as mean ± standard error. The values of population of 
Firmicutes and Bacteroidetes in feces of mice and the rate of two microorganisms 
(Firmicutes/Bacteroidetes) were presented as mean ± standard error. Data were 
subjected to one-way ANOVA with Dunnett’s multiple comparison of means test. 
Differences showing p < 0.05 were considered significant. Statistical analysis was 
performed using Ekuseru-Toukei 2010 Version.1.11 (Social Survey Research 
Information, Tokyo, Japan). 
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Results 
 
1. Improvement of DSS-induced colitis by sake autofocusing fractions. 
  After autofocusing of 5-fold sake concentrate, autofocusing fraction (Fr.) 1–8 showed 
approximately pH 3 and sharp pH gradient from 3 to 12 was formed between Fr. 8–10 
(Figure 1A). Approximately 80% of total peptides were recovered in Fr. 8 and 9 (Figure 
1B). As shown in Figure 1C, peptides in the acidic fractions (Fr. 1–8) consisted of 
higher levels of acidic amino acids such as glutamic acid after HCl hydrolysis, and 
peptides in the basic fractions (Fr. 10) consisted of higher levels of basic amino acids 
such as lysine compared with the other fractions, which indicate that the peptides in 
sake were fractionated on the basis of their isoelectric points. To make flat pH region (Fr. 
1–8), high amounts of non-peptide acidic compounds, such as organic acids, might be 
present in the sample. Approximately 60% of sugars were also distributed in Fr. 8 and 9. 
On the basis of these results, autofocusing Fr. 1–5 and 6–7 were mixed and used for 
animal experiment, respectively. Fr. 8, 9, and 10 were individually used for the animal 
experiment. Autofocusing fractions were mixed with ethanol to give 75% (v/v) to 
remove agarose that was derived from the separator of autofocusing. The supernatants 
were collected and concentrated by a rotary evaporator to remove ethanol. The 
concentrates were diluted with distilled water to give 3.0 mg peptides (total amino 
acids)/mL (30 mg/kg body weight per day) for the animal experiment. 
  As shown in Figure 2, DSS treatment induced colitis as indicated by significant 
increase of DAI score. Administration of Fr. 6–7, 8, and 9 significantly moderated body 
weight loss. Only Fr. 8 significantly decreased the DAI score. There was no significant 
difference in colon length among all groups. On the other hands, crude sake concentrate 
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exerted no significant protective effect against DSS-induced colitis in mice. 
 
2. Improvement of DSS-induced colitis by RP-LC fractions. 
  Compounds in autofocusing Fr. 8 (3.0 mg peptides (total amino acids)/mL, 80 mL) 
were further fractionated by RP-LC. Elution profile is shown in Figure 3. After elution 
of non-absorbed compounds in the RP-LC column, absorbed compounds were eluted by 
increasing acetonitrile concentration. Most of free amino acids and sugars are eluted in 
the non-absorbed fraction. Peptide content can be estimated by subtracting free amino 
acids from total amino acids in HCl hydrolysate. Peptides were eluted in both 
non-absorbed and absorbed fractions. As shown in Figure 3C, UV absorbance peak was 
observed at 20–21 min. On the basis of these results, four fractions (I–IV) were 
collected as follows; Fr. I (Fr. 0.5–14), II (Fr. 14.5–17), III (Fr. 17.5–19.5), and IV (Fr. 
20–31). Each fraction was freeze dried to remove acetonitrile and then dissolved into 80 
mL of distilled water. Two hundred microliters of the Fr. I–IV were administered to 
mice with DSS-induced colitis. 
  As shown in Figure 4, administration of Fr. III significantly moderated body weight 
loss compared with DSS + control group. DAI scores of Fr. I–IV groups had no 
significant difference compared with DSS + control group, whereas administration of 
crude Fr. 8 significantly decreased the DAI score. There was no significant difference in 
colon length among all groups. On the basis of these results, Fr. III was used for 
identification of constituting pyroglutamyl peptides. 
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3. Identification of pyroglutamyl peptides in Fr. III and their protective effect 
against DSS-induced colitis. 
  Peptides in the Fr. III were first resolved by SEC. As shown in Figure 5A, 
approximately 75% of peptides were eluted in Fr. 31–36. Pyroglutamyl peptides in these 
fractions were separated by the solid phase extraction and resolved by RP-HPLC. 
  As shown in Figure 5B, major peaks marked a, b, and c by RP-HPLC were collected. 
The pyroglutamyl peptides in Fr. a, b, and c were digested with pyroglutamate 
aminopeptidase. The digests and non-digests were reacted with PITC. The resultant 
PTC derivatives were resolved by second RP-HPLC. Peaks marked with a’, b’, and c’ 
were appeared in the only enzyme digest of Fr. a, b, and c (Figure 5C). These PTC 
derivatives were identified by Edman degradation as follows; peak a’, 
pyroglutamyl-tyrosine (pyroGlu-Tyr), peak b’, pyroglutamyl-asparaginyl-isoleucine 
(pyroGlu-Asn-Ile), and peak c’, 
pyroglutamyl-asparaginyl-isoleucyl-asparagyl-asparaginyl-proline 
(pyroGlu-Asn-Ile-Asp-Asn-Pro). Peaks marked with asterisks in Figure 5B and C did 
not yield significant sequence by Edman degradation even after pyroglutamate 
aminopeptidase digestion. 
  Three identified pyroglutamyl peptides were chemically synthesized and 
administered to DSS-induced colitis mice. As shown in Figure 6, administration of these 
pyroglutamyl peptides did not significantly moderate the body weight loss compared 
with DSS + control group. On the other hand, administration of pyroGlu-Tyr and 
pyroGlu-Asn-Ile significantly moderate the colon shortening at 1.0 mg/kg body weight 
(p < 0.05 and p < 0.01, respectively). pyroGlu-Asn-Ile significantly decreased DAI 
score compared with DSS + control group in dose dependent manner. On the other hand, 
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pyroGlu-Asn-Ile-Asp-Asn-Pro did not exert any protective effects on the colitis. 
  The contents of pyroGlu-Leu, pyroGlu-Tyr, pyroGlu-Asn-Ile, and 
pyroGlu-Asn-Ile-Asp-Asn-Pro in samples for animal experiment were determined using 
LC-MS/MS. Doses of these peptides for DSS-induced colitis mice are shown in Table 1. 
When sake concentrate and autofocusing Fr. 8 were administered to mice, the doses of 
pyroGlu-Leu were higher than 0.1 mg/kg body weight. On the other hand, it was less 
than 0.01 mg/kg body weight, when Fr. III was used. Doses of pyroGlu-Tyr and 
pyroGlu-Asn-Ile-Asp-Asn-Pro were higher than 0.1 mg/kg body weight, only when 
autofocusing Fr. 8 was used. In all cases, doses of pyroGlu-Asn-Ile were less than 0.1 
mg/kg body weight. 
 
4. Effects of pyroglutamyl peptides in sake on enteric microbiota. 
  DSS treatment increased population of Firmicutes and decreased that of 
Bacteroidetes in the inner content of the colon compared to DSS – normal group. 
Consequently, ratio of Firmicutes to Bacteroidetes significantly increased. 
Administration of pyroGlu-Asn-Ile significantly normalized the ratio, whereas 
pyroGlu-Tyr did not significantly change the ratio. 
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Discussion 
 
  While crude sake without fractionation did not show any significant protective effects 
against DSS-induced colitis, some autofocusing fractions exerted beneficial and 
negative effects by oral administration, respectively. These facts suggest presence of 
some compounds which have positive and negative effects on the colitis in sake. In 
order to identify pyroglutamyl peptides with protective activity against acute colitis, 
active autofocusing fraction was further fractionated by using RP-LC. pyroGlu-Tyr, 
pyroGlu-Asn-Ile, and pyroGlu-Asn-Ile-Asp-Asn-Pro were identified in the active 
fraction. Chemically synthesized pyroGlu-Tyr and pyroGlu-Asn-Ile significantly 
attenuated colitis-induced shortening of colon. pyroGlu-Asn-Ile also significantly 
decreased DAI score, which indicate that these peptides in sake have potential for 
improvement of acute colitis. 
  Wada et al. (2013) have demonstrated that pyroGlu-Leu significantly moderates 
DSS-induced colitis in mice by oral administration at 0.1 mg/kg body weight. However, 
it did not exert the beneficial activity higher than 0.5 and lower than 0.05 mg/kg body 
weight, respectively. On the other hand, the present study demonstrates that 
pyroGlu-Asn-Ile exerts the protective effect in dose dependent manner at least from 0.1 
to 1.0 mg/kg body weight. Then, pyroGlu-Asn-Ile shows beneficial effect in the same 
animal model in wider dose range than pyroGlu-Leu, which might be advantage in 
practical use to pyroGlu-Leu. 
  pyroGlu-Leu in sake was recovered in the autofocusing Fr. 8 and RP-LC Fr. IV (data 
not shown). However, administration of RP-LC Fr. IV (dose of pyroGlu-Leu; 0.31 
mg/kg body weight) did not exert the protective effect against the colitis possibly due to 
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higher dosage of pyroGlu-Leu. On the other hand, administration of autofocusing Fr. 8 
(dose of pyroGlu-Leu; 0.46 mg/kg body weight) exerted the protective effect possibly 
due to presence of other pyroglutamyl peptides such as pyroGlu-Tyr and 
pyroGlu-Asn-Ile. These facts suggest that pyroGlu-Tyr and pyroGlu-Asn-Ile can 
modulate biological activity of pyroGlu-Leu or coordinately act with pyroGlu-Leu in 
this animal model. 
  Wada et al. (2013) have demonstrated that ratio of Firmicutes to Bacteroidetes, two 
major phylums of colonic microbiota, dramatically increases in the mice with 
DSS-induced colitis, and administration of pyroGlu-Leu normalizes the ratio. In the 
present study, administration of pyroGlu-Asn-Ile also normalized the colonic microbiota 
in the DSS-induced colitis mice. On the other hand, pyroGlu-Tyr did not affect the 
microbiota, while it moderated the colitis-induced shortening of colon. These facts 
suggest that pyroGlu-Tyr might exert protective effect by different mechanism from 
pyroGlu-Leu and pyroGlu-Asn-Ile. 
  Mechanism for the normalization of colonic microbiota in mice with DSS-induced 
colitis by pyroGlu-Leu and pyroGlu-Asn-Ile have remained to be solved. It is, however, 
unlikely that these peptides have a direct antimicrobial effect on colonic microbiota, as 
these peptides modulated microbiota in low doses (0.1–1.0 mg/kg body weight). 
Alternatively, it could be assumed that pyroGlu-Leu and pyroGlu-Asn-Ile might 
indirectly normalize colonic microbiota through the modulation of host innate immune 
or/and inflammatory systems. The further studies on the effect of administration of 
pyroGlu-Leu and pyroGlu-Asn-Ile on production of host antimicrobial compounds and 
also immune response under physiological and pathological conditions are in progress. 
  The present study demonstrated that sake contains compounds with protective and 
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negative effects on colitis. The preparation with higher protective activity against colitis 
could be prepared by fractionation of sake as shown in the present study and also by 
optimizing fermentation process, which will be described in the following chapter. 
pyroGlu-Leu, pyroGlu-Asn-Ile, and other pyroglutamyl peptides may be used as good 
markers to predict the efficacy and also to explore the mechanism for the protective 
effect against colitis. 
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Figures and tables 
 
 
Figure 1. Fractionation of sake concentrate by ampholite-free preparative isoelectric focusing. pH values 
(A). Contents of total peptides (total constituent amino acids after HCl hydrolysis) (B). Ratio of basic, 
neutral, and acidic amino acids to the total amino acids (C). Contents of sugar as glucose equivalent (D). 
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Figure 2. Effects of sake autofocusing fractions on DSS-induced colitis in 
mice. Body weight change (A). Colon length (B). Disease activity index 
(DAI) score (C). Values are presented as mean ± standard error. DSS −, 
normal group without DSS; DSS +, control group with DSS; crude, 
five-folds sake concentrate. Doses of all samples were 30 mg/kg peptides. 
* and ** represent p < 0.05, and < 0.01 when compared with DSS + by 
Dunnett’s test. 
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Figure 3. Fractionation of sake autofocusing Fr. 8 by preparative reversed-phase liquid chromatography. 
Arrows indicate start of acetonitrile gradient. Contents of free amino acids and total constituent amino 
acids of HCl hydrolysate in each fraction (A). Content of sugar as glucose equivalent (B). UV 
absorbance of each fraction (C). 
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Figure 4. Effects of preparative reversed-phase liquid chromatography 
(RP-LC) Fr. I–IV on DSS-induced colitis in mice. Body weight change 
(A). Colon length (B). Disease activity index (DAI) score (C). Values are 
presented as mean ± standard error. DSS −, normal group without DSS; 
DSS +, control group with DSS; Crude Fr. 8, sake autofocusing Fr. 8. 
Dose of crude Fr. 8 was 30 mg/kg peptides. * and ** represent p < 0.05, 
and < 0.01 when compared with DSS + by Dunnett’s test. 
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Figure 5. Identification of pyroglutamyl peptides in RP-LC Fr. III. Elution profile of peptides in Fr. III 
by size exclusion chromatography (SEC) using Superdex Peptide 10/30 GL (GE Healthcare) (A). 
Contents of peptide are expressed as the sum of total constituent amino acids in each SEC fraction after 
HCl hydrolysis. Isolation of pyroglutamyl peptides in SEC Fr. 31–36 by RP-HPLC (B). Fr. a, b, and c in 
panel B were digested with pyroglutamate aminopeptidase and derivatized with phenyl isothiocyanate. 
The resultant phenyl thiocarbamyl-amino acids/-peptides were resolved by second RP-HPLC (C). +, 
pyroglutamate aminopeptidase digests; −, non-digests of each Fr. a, b, and c. Peaks marked with a’, b’, 
and c’ in panel C yielded phenyl thiohydantoin-amino acids upon Edman degradation. Peaks marked 
with asterisks in panel B and C did not yield significant sequence by the Edman degradation even after 
pyroglutamate aminopeptidase digestion.  
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Figure 6. Effects of pyroGlu-Tyr (pEY), pyroGlu-Asn-Ile (pENI), and 
pyroGlu-Asn-Ile-Asp-Asn-Pro (pENIDNP) on DSS-induced colitis in 
mice. Body weight change (A). Colon length (B). Disease activity index  
(DAI) score (C). Values are presented as mean ± standard error. DSS −, 
normal group without DSS; DSS +, control group with DSS. * and ** 
represent p < 0.05, and < 0.01 when compared with DSS + by Dunnett’s 
test. 
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Figure 7. Population of Firmicutes and Bacteroidetes (A) and the rate of two phylums 
(Firmicutes/Bacteroidetes) (B) in the inner content of the colon in DSS-induced colitis mice with 
administration of chemically pyroGlu-Tyr (pEY) and pyroGlu-Asn-Ile (pENI). Doses of these peptides 
are 1.0 mg/kg body weight. Values are presented as mean ± standard error. DSS −, normal group 
without DSS; DSS +, control group with DSS. * and ** represent p < 0.05, and < 0.01 when compared 
with DSS + by Dunnett’s test. 
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Table 1. Doses of pyroglutamyl peptides by administration of crude sake concentrate and 
fractions to mice 
Samples 
Pyroglutamyl peptides (mg/kg body weight) 
pEL pEY pENI pENIDNP 
Sake concentrate 0.267 0.095 0.017 0.039 
Autofocusing Fr. 8 0.460 0.195 0.033 0.123 
RP-LC Fr. III 0.003 0.011 0.014 0.040 
pEL, pyroGlu-Leu; pEY, pyroGlu-Tyr; pENI, pyroGlu-Asn-Ile; pENIDNP, 
pyroGlu-Asn-Ile-Asp-Asn-Pro. 
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Chapter 4 
Preparation of rice-fermented beverage with protective activity against 
DSS-induced colitis in mice 
 
Introduction 
 
  It has been demonstrated that intake of some food (Osman et al., 2008; Shizuma et al., 
2011), dietary peptides (Young et al., 2012; Lee, et al., 2009), amino acids (Vicario et al., 
2007) can attenuate colitis in animal models. However, relatively high doses have been 
suggested to exert the protective effect against colitis by ingestion of these compounds. 
Kanauchi et al. have demonstrated that administration of germinated barley foodstuff 
(GBF) attenuates drug-induced constipation (1998 a) and colitis (1998 b) in animal 
models. In addition, randomized, open-labeled human study has demonstrated that daily 
consumption of 20–30 g of GBF for 4 weeks moderates colonic pathology of ulcerative 
colitis patients, which is one of inflammatory bowel disease (IBD) (Kanauchi et al., 
2002). On the basis of these evidence, GBF was certified as a Food for Special Dietary 
Uses (FOSDU) by Individual Approval System in Japan in 2000, which indicates that 
IBD can be, at least partially, controlled by taking functional food. However, the GBF 
has not been popular for IBD patients and has been withdrawn from FOSDU. Therefore, 
new functional food for IBD patients has been demanded. It should exert beneficial 
activity preferably by ingestion of small dosage for chronic use. 
  As shown in previous chapters, sake contains pyroglutamyl peptides with the 
protective activity against DSS-induced colitis in mice; pyroGlu-Leu, pyroGlu-Tyr, and 
pyroGlu-Asn-Ile. It has been suggested that sake yeast (Saccharomyces cerevisiae) does 
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not play a significant role in production of these peptides. These peptides can be 
produced by proteolytic digestion of rice proteins by Aspergillus oryzae proteases 
during sake brewing. Therefore, there is a possibility that low-alcohol fermented 
beverage containing these pyroglutamyl peptides can be produced by fermentation of 
steamed rice with A. oryzae. 
  The final goal of this study is to develop a low-alcohol functional beverage with the 
protective activity against IBD by modified sake brewing process. Various types of 
fermented steamed rice with food-grade A. oryzae were prepared and checked for their 
protective activity against DSS-induced colitis in mouse model. 
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Materials and methods 
 
1. Food materials. 
  Food-grade lactic acid was obtained from Musashino Chemical Laboratory (Tokyo, 
Japan). Dried kojis, which is the steamed rice inoculated with A. oryzae, was kind gift 
from Tokushima Seikiku (Tokushima, Japan). The rice used for koji had been polished 
to 60 and 90% of brown rice. Rice polished to 90% was also used for preparation of 
steamed rice.  
 
2. Reagents. 
  Dextran sulfate sodium (DSS, average molecular weight 8,000) was purchased from 
Seikagaku (Tokyo, Japan). Acetonitrile (HPLC grade), phenyl isothiocyanate (PITC) 
were purchased from Wako Chemicals (Osaka, Japan). Triethylamine (TEA) was 
purchased from Thermo Fisher Scientific (Waltham, MA). Other reagents used were of 
analytical grade or better. 
 
3. DSS-induced colitis in mice. 
  The animal experiment of DSS-induced colitis was conducted by the same 
procedures as described in chapter 3. All animals were treated and cared for in 
accordance with the National Institutes of Health’s (NIH) guidelines for the use of 
experimental animals. All experimental procedures were approved by the Animal Care 
Committee of Kyoto Prefectural University of Medicine (M23–37, M24–25, Kyoto, 
Japan). Supernatants prepared from fermented rice products described below were 
diluted with distilled water to give 0.3 mg peptides (total amino acids in HCl 
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hydrolysate)/mL (3 mg/kg body weight), and administered to the mice.  
 
4. Preparation of fermented rice. 
  Fermented rice was prepared by different conditions and from different materials by 
Shotoku Brewery (Kyoto, Japan). Two types of koji, which were made from rice 
polished to 60 and 90% of brown rice and referred to koji 60 and koji 90, respectively, 
were used. In low-temperature fermentation (LTF), koji 60 or koji 90, water, and lactic 
acid were mixed in a ratio as shown in Table 1. The mixtures were fermented at 10°C or 
20°C for 1 week or 2 weeks. In high-temperature fermentation (HTF), the koji 90 was 
mixed with steamed rice and water as shown in Table 1. The steamed rice was made 
from the rice polished to 90%. The rice was washed and soaked in water overnight, and 
then steamed at 120°C for 1 h and cooled until manageable. The mixture was fermented 
at 55°C for 4 h and followed additional fermentation at 40°C, 50°C, and 55°C, 
respectively. Aliquots of fermented products were collected 1, 2, and 3 h after the 
second fermentation. 
 
5. Determination of pyroglutamyl peptides. 
  Aliquots of the LTF and HTF products (25 g) were homogenized with 25 mL of 
distilled water using a glass homogenizer. The supernatants were collected after 
centrifugation at 2,000 rpm for 10 min and diluted at 100 folds with ultrapure water, and 
clarified by passing through a filter (Cosmonice filter W, 4 mm i.d., 0.45 μm pore size, 
Nacalai Tesque, Kyoto, Japan) The contents of pyroGlu-Leu, pyroGlu-Tyr, 
pyroGlu-Asn-Ile, and pyroGlu-Asn-Ile-Asp-Asn-Pro in these samples were determined 
using liquid chromatography-tandem mass spectrometry as described in chapter 3. 
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6. Amino acid analysis. 
  Vapor-phase 6 M HCl hydrolysis and amino acid analysis using PITC derivatization 
were performed according to the method as described in chapter 2. Peptide content was 
expressed as sum of total constituent amino acids after HCl hydrolysis. 
  
7. Statistical analysis. 
  The value of body weight change, colon length, and disease activity index (DAI) 
score of DSS-induced colitis mice were presented as mean ± standard error. Data were 
subjected to one-way ANOVA with Dunnett’s multiple comparison of means test. 
Differences showing p < 0.05 were considered significant. Statistical analysis was 
performed using Ekuseru-Toukei 2010 Version.1.11 (Social Survey Research 
Information, Tokyo, Japan).  
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Results 
 
1. Pyroglutamyl peptides in fermented rice. 
  Contents of pyroGlu-Leu, pyroGlu-Tyr, pyroGlu-Asn-Ile, and 
pyroGlu-Asn-Ile-Asp-Asn-Pro in LTF products are shown in Figure 1. Pyroglutamyl 
di-peptides, pyroGlu-Leu and pGlu-Tyr, increased after longer fermentation period and 
at 20°C. The contents of these peptides in LTF products from koji 90 were higher than 
those from koji 60. Content of pyroglutamyl tri-peptide, pyroGlu-Asn-Ile, increased 
during 2 weeks and were higher by fermentation at 10°C. Polishing rate of rice for koji 
did not affect the content of pyroGlu-Asn-Ile. On the other hand, content of 
pyroGlu-Asn-Ile-Asp-Asn-Pro decreased by longer fermentation period at 20°C. At 
10°C, pyroGlu-Asn-Ile-Asp-Asn-Pro did not exceed approximately 1 μM. 
  As shown in Figure 2, HTF products after first fermentation at 55°C contained 
pyroGlu-Leu and pyroGlu-Tyr at approximately 20 and 4 μM, respectively, which did 
not increase during second fermentation periods at different temperature. On the other 
hand, pyroGlu-Asn-Ile and pyroGlu-Asn-Ile-Asp-Asn-Ile were not detected in all HTF 
samples. 
  
2. Improvement of DSS-induced colitis by fermented rice. 
  LTF products from koji 60 at 10°C for 2 weeks, koji 90 at 10°C and 20°C for 2 weeks, 
and HTF product without second fermentation step were evaluated for protective 
activity against colitis. These LTF products are referred to LTF (temperature)-koji 
(recovery), ex LTF 20-koji 90 in the following section. The soluble fractions of these 
samples were administered (3 mg peptides (total amino acids in HCl hydrolysate)/kg 
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body weight) for the mice with DSS-induced colitis. As shown in Figure 3, DSS 
treatment induced colitis as indicated by significant decrease of body weight gain, colon 
length, and significant increase of DAI score. Administration of LTF 20-koji 60 
significantly attenuated body weight loss and decreased DAI score compared with DSS 
+ control group. LTF 20-koji 90 tended to moderate body weight loss (p = 0.08) and 
significantly decreased DAI score. There was no significant difference in colon length 
between DSS + control group and each sample group. On the other hand, administration 
of HTF product showed no significant protective effect against DSS-induced colitis in 
mice. 
  Doses of pyroGlu-Leu, pyroGlu-Tyr, pyroGlu-Asn-Ile, and 
pyroGlu-Asn-Ile-Asp-Asn-Pro by administration of LTF and HTF products to mice are 
presented in Table 2. Similar doses of pyroGlu-Leu were administered to all groups. The 
doses of pyroGlu-Try were almost same except for LTF 10-koji 90 group. Doses of the 
pyroglutamyl tri- and hexa-peptides also did not so change between LTF groups. 
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Discussion 
 
  While pyroGlu-Leu and pyroGlu-Tyr were presented in all LTF and HTF products, 
tri- and hexa-pyroglutamyl peptides, pyroGlu-Asn-Ile and 
pyroGlu-Asn-Ile-Asp-Asn-Pro, were observed only in the LTF products. It has been 
reported that optimal temperature for extracellular proteases of A. oryzae including 
carboxypeptidase is 50–60°C (Blinkovsky et al., 1999). PyroGlu-Asn-Ile and 
pyroGlu-Asn-Ile-Asp-Asn-Pro might be degraded by the carboxypeptidase in HTF 
products. In the LTF products, pyroGlu-Leu and pyroGlu-Tyr increased by longer 
fermentation period, and higher temperature (20°C). On the other hand, 
pyroGlu-Asn-Ile and pyroGlu-Asn-Ile-Asp-Asn-Pro did not increase by the higher 
temperature. Therefore, fermentation temperature is critical to control composition of 
di-, tri-, and hexa-pyroglutamyl peptides in the products. For production of 
pyroGlu-Asn-Ile and pyroGlu-Asn-Ile-Asp-Asn-Pro, higher temperature than 20°C is 
nor preferable. 
  Three LTF products, LTF 10 and 20-koji 90 and LTF 60-koji 20, which had higher 
content of pyroGlu-Leu than sake (chapter 2), and one HTF product without second 
fermentation were examined for the protective effects against DSS-induced colitis in 
mice. In chapter 3, dose of pyroGlu-Leu by administration of sake concentrate (30 mg 
peptides (total amino acids)/kg body weight) was higher than 0.1 mg/kg body weight. 
Synthesized pyroGlu-Leu exerted the protective effect against the colitis in the same 
animal model by oral administration at 0.1 mg/kg body weight, while higher dose did 
not show beneficial effect (Wada et al., 2013). Therefore, dose of pyroGlu-Leu should 
be less than 0.l mg/kg body weight for practical use. Therefore, the LTF products and 
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HTF product were administered to the mice at 3 mg peptides (total amino acids)/kg 
body weight, which is 1/10 of the dose in the animal experiments in previous chapter. 
Doses of four pyroglutamyl peptides by administration of LTF and HTF products are 
shown in Table 2. The doses of active pyroglutamyl peptides were considerably lower 
than effective doses evaluated by single administration of synthesized peptides as 
shown in chapter 3. 
  As shown in Figure 3, HTF product showed no significant protective effect by the 
present dose possibly due to the smaller doses of pyroGlu-Leu and pyroGlu-Tyr 
compared to optimum doses (Table 2). On the other hand, unexpectedly, administration 
of LTF 20-koji 60 and 90, containing pyroGlu-Asn-Ile and 
pyroGlu-Asn-Ile-Asp-Asn-Pro in addition to pyroGlu-Leu and pyroGlu-Tyr, 
significantly moderated DSS-induced colitis in mice, while doses of pyroGlu-Leu and 
pyroGlu-Tyr by administration of these LTF products were comparable to those by 
administration of HTF product (Table 2). The previous study (chapter 3) also indicated 
that administration of pyroGlu-Leu over optimum dose with presence of small doses of 
pyroGlu-Asn-Ile and pyroGlu-Asn-Ile-Asp-Asn-Pro moderated to the colitis, while in 
the absence of pyroGlu-Asn-Ile and pyroGlu-Asn-Ile-Asp-Asn-Pro did not show the 
protective effect. These facts suggest presence of pyroGlu-Asn-Ile and 
pyroGlu-Asn-Ile-Asp-Asn-Pro in smaller dose, which did not exert the protective effect 
by single administration of synthesized ones, might cooperatively enhance the 
protective effect with pyroGlu-Leu and pyroGlu-Tyr. Alternatively, other compounds in 
the LTF products, such as peptides with amino group, oligosaccharides and etc., might 
be also involved in the protective effect. Further studies on the protective effect against 
colitis by combination of pyroGlu-Leu, pyroGlu-Tyr, pyroGlu-Asn-Ile, 
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pyroGlu-Asn-Ile-Asp-Asn-Pro, and other compounds in the LTF products are in 
progress.  
  In the previous study (chapter 3), alcohol-free sake concentrate without fractionation 
did not exert the protective effect against DSS-induced colitis in mice. The present 
study demonstrated that some LTF products without purification step exerted the 
protective effect in small dose corresponding to less than 20 mL per day for human 
which is simply estimated on the basis of effective dose/kg body weight. The LTF 
product, which is a low-alcohol fermented food and prepared by using classical method 
for Shubo (sake yeast starter) production, has stronger potential to control human IBD 
as functional fermented beverage in comparison to sake (Japanese rice wine) or HTF 
product, which is mimicking Japanese sweet rice-fermented beverage, amazake. After 
identification of active compounds, their effective dose, and elucidation of underlying 
mechanism, formulated LTF product is necessary for human trial.  
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Figures and tables 
  
Figure 1. Determination of contents of pyroGlu-Leu (pEL), pyroGlu-Tyr (pEY), pyroGlu-Asn-Ile (pENI), 
and pyroGlu-Asn-Ile-Asp-Asn-Pro (pENIDNP) in low-temperature fermentation (LTF) products. Koji 60 
and 90 were used. Black circles show the fermentation at 10°C, and white circles show at 20°C.  
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Figure 2. Determination of contents of pyroGlu-Leu (pEL), pyroGlu-Tyr (pEY), pyroGlu-Asn-Ile (pENI), 
and pyroGlu-Asn-Ile-Asp-Asn-Pro (pENIDNP) in high-temterature fermentation (HTF) products after 
second fermentation. Time “0 h” is the HTF products 4 h after first fermentation at 55°C. Black squares 
show the HTF products by additional fermentation at 40°C, shaded squares show at 50°C, and white 
squares show at 55°C. “n.d.” shows no detectable amount.  
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Figure 3. Effects of rice-fermented products at low-temperature 
fermentation (LTF) and high-temperature fermentation (HTF) on 
DSS-induced colitis in mice. Body weight change (A). Colon length (B). 
Disease acitvity index (DAI) score (C). Values are presented as mean ± 
standard error. DSS −, normal group without DSS; DSS +, control group 
with DSS; HTF, the HTF product 4 h after first fermentation at 55°C 
without additional fermentation (0 h in Figure 1). * and ** represent p < 
0.05, and < 0.01 when compared with DSS + group by Dunnett’s test. 
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Table. 1 Composition of materials for rice-fermented products 
Materials 
Mixing rate (%) 
Low-temperature fermentation High-temperature fermentation 
Koji (w/w)*
 
44.7 31 
Steamed rice (w/w)* 0 13.8 
Water (v/w) 55.0 55.2 
Lactic acid (v/w) 0.3 0 
*Contents of koji and steamed rice were expressed as the content to polished rice before 
steaming. 
 
 
 
Table 2. Doses of four pyroglutamyl peptides by administration of LTF and HTF products to mice 
(μg/kg  
body weight) 
HTF 
 
LTF 
0 h 
 
60%、20°C 90%、10°C 90%、20°C 
pEL 4.90 
 
4.98 4.24 4.74 
pEY 1.09 
 
0.77 0.30 1.04 
pENI – 
 
0.04 0.04 0.03 
pENIDNP – 
 
0.16 0.13 0.09 
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Chapter 5 
General discussion and conclusion 
 
  In this study, nearly 20 short-chain pyroglutamyl peptides were identified in Japanese 
rice wine, sake, which first provides basic knowledge about the structures of 
pyroglutamyl peptides in sake. Interestingly, pyroGlu-Leu, which was first identified in 
wheat gluten hydrolysate as a protective compound against acute hepatitis and colitis in 
animal models, is one of the major constituents of pyroglutamyl peptides in sake. These 
findings suggest that sake and its constituents might have potential to exert beneficial 
activity for human health. In addition, there is a possibility that other pyroglutamyl 
peptides might have beneficial activities. 
  The crude alcohol-free sake concentrate did not exert the protective effect against the 
animal colitis. Fractionation using ampholite-free preparative isoelectric focusing, 
autofocusing, revealed that sake contains compounds with positive and negative effects 
on the animal colitis. Active fraction obtained by preparative reversed phase-liquid 
chromatography with the protective activity consisted of pyroGlu-Tyr, pyroGlu-Asn-Ile, 
and pyroGlu-Asn-Ile-Asp-Asn-Pro. Chemically synthesized pyroGlu-Tyr and 
pyroGlu-Asn-Ile significantly attenuated the colitis. The DSS-induced colitis 
dramatically changes ratio of Firmicutes to Bacteroidetes in the mouse colon, which are 
two major phylums of colonic microbiota. PyroGlu-Leu and pyroGlu-Asn-Ile 
normalized the colonic microbiota in the DSS-induced colitis mice by oral 
administration of unexpectedly low doses (0.1–1.0 mg/kg body weight). On the other 
hand, pyroGlu-Tyr did not significantly affect on the microbiota. Therefore, sake 
contains some protective pyroglutamyl peptides against the colitis based on different 
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mechanisms. The mechanisms for modulation of colonic microbiota by small doses of 
pyroGlu-Leu and pyroGlu-Asn-Ile remain to be solved. However, it is unlikely to 
assume that these peptides directly modulate growth of colonic microorganisms by 
small dose. Possibly these peptides might affect host innate immune or/and 
inflammatory responses. Elucidation of the effect of food compounds such as 
pyroGlu-Leu and pyroGlu-Asn-Ile to host intestinal cells responsible for the innate 
immune and inflammatory responses might explore a new target for health promotion 
by food.  
  The present study demonstrates that proteases from Aspergillus oryzae (koji) play a 
significant role in production of pyroGlu-Leu, and sake yeast (Saccharomyces 
cerevisiae) is not significantly involved in production of pyroGlu-Leu. On the basis of 
these facts, pyroglutamyl peptides were produced by high-temperature fermentation 
(HTF) and low-temperature fermentation (LTF) of koji. The HTF and LTF of koji 
correspond to production of Japanese traditional sweet fermented rice beverage, 
amazake, and to classical production of shubo (sake yeast starter). PyroGlu-Asn-Ile and 
pyroGlu-Asn-Ile-Asp-Asn-Pro were observed only in the LTF product, while 
pyroGlu-Leu and pyroGlu-Tyr were presented in all LTF and HTF products. Although 
doses of pyroGlu-Leu and pyroGlu-Tyr by administration of HTF and LTF products 
were lower than optimum dose for each synthesized peptide, the LTF products exerted 
the protective effect against colitis in mice, while HTF product did not show the effect. 
These results suggest that presence of pyroGlu-Asn-Ile and 
pyroGlu-Asn-Ile-Asp-Asn-Pro in smaller dose might cooperatively enhance the 
protective effect against colitis with pyroGlu-Leu and pyroGlu-Tyr. The identification of 
pyroglutamyl peptides which have the protective effect against colitis in animal model 
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with single administration enable to investigate the beneficial effect by combination of 
these peptides and other food compounds, which would explore how complicated food 
system exert beneficial effects for human health. 
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